Equity Profile

CSTL

Castle Biosciences, Inc.

Health CareHealth Care Services$697.0M

Aug3Mon

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Castle Biosciences, Inc. is a healthcare company focused on providing innovative diagnostic tests for skin cancer and other diseases....

Key Metrics to Watch

EPS

Earnings per share (EPS) is a key indicator of the company's profitability and financial health.

N/A

Revenue Growth

Revenue growth will indicate how well the company is expanding its business and capturing market share.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

CSTL Q2-2026 Earnings Preview

Context

Company Snapshot

Castle Biosciences, Inc. is a healthcare company focused on providing innovative diagnostic tests for skin cancer and other diseases. With a market cap of $1 billion, it plays a crucial role in improving patient outcomes through advanced testing solutions in the healthcare services sector.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+1.24%

Avg Stock Reaction

+0.50%

Last Quarter Recap

In Q1-2026, Castle Biosciences reported an EPS of -$0.49, which was better than the expected -$0.56, resulting in a positive surprise of 12.5%. The stock reacted positively, gaining 0.61% the next day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautiously optimistic ahead of the earnings report, given the company's recent performance that has consistently beaten EPS estimates. However, there is uncertainty regarding revenue figures as no estimates are available.

Bull Case

If Castle Biosciences continues its trend of beating EPS estimates, it could indicate strong operational performance and investor confidence, potentially driving the stock higher.

Bear Case

On the other hand, if the company fails to meet expectations or provides weak guidance, it could lead to a significant drop in stock price, especially given the high implied volatility in the options market.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026, and how does it compare to previous quarters?

Given the company's history of beating EPS estimates, this will be a critical indicator of ongoing operational success.

What insights can management provide on revenue growth and market expansion?

Understanding revenue growth is vital for assessing the company's ability to scale and compete effectively in the healthcare market.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Castle Biosciences' potential for revenue growth based on its recent performance trends, which suggest a stronger operational capacity than reflected in current estimates.

Supporting Evidence

The company has consistently beaten EPS estimates, indicating stronger-than-expected performance.

Options pricing suggests a significant move is expected, which may not align with the consensus view of stability.

Key Risk

If the company reports an EPS significantly better than -$0.40, it could challenge the current cautious sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Castle Biosciences can maintain its positive earnings surprises in a competitive healthcare landscape.

Bull Confirmed If

An EPS of -$0.40 or better would confirm the bull case, suggesting strong operational performance.

Bear Confirmed If

An EPS worse than -$0.60 would confirm the bear case, indicating potential issues in the business.

Pre-Earnings Positioning

Options Market

Implied Move

±29.41%

Historical Avg

±2.5%

Pricing rich

The options market is pricing in a substantial move, suggesting that traders expect significant volatility around the earnings announcement.

Options are pricing ±29.4% while CSTL has averaged ±2.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

88.6%

Calls (300)P/C Ratio: 1.00Puts (0)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Castle Biosciences beats expectations, history suggests the stock could rise by about 1.02% on the following day, confirming positive market sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may see a muted reaction as investors await further guidance from management.

Miss

If the company misses expectations, history suggests a potential decline of around 3.10%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches or market expansions.
2Management's commentary on competitive pressures in the healthcare sector.
3Insights into customer adoption rates of their diagnostic tests.
4Any changes in operational costs or margins that could affect profitability.
5Future guidance on revenue expectations for the upcoming quarters.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Castle Biosciences, Inc. is a healthcare company focused on providing innovative diagnostic tests for skin cancer and other diseases....

Key Metrics to Watch

EPS

Earnings per share (EPS) is a key indicator of the company's profitability and financial health.

N/A

Revenue Growth

Revenue growth will indicate how well the company is expanding its business and capturing market share.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

CSTL Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+1.24%

Avg Stock Reaction

+0.50%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Castle Biosciences continues its trend of beating EPS estimates, it could indicate strong operational performance and investor confidence, potentially driving the stock higher.

Bear Case

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026, and how does it compare to previous quarters?

Given the company's history of beating EPS estimates, this will be a critical indicator of ongoing operational success.

What insights can management provide on revenue growth and market expansion?

Understanding revenue growth is vital for assessing the company's ability to scale and compete effectively in the healthcare market.

Edge

What the Street Is Missing

Why consensus could be wrong

Supporting Evidence

The company has consistently beaten EPS estimates, indicating stronger-than-expected performance.

Options pricing suggests a significant move is expected, which may not align with the consensus view of stability.

Key Risk

If the company reports an EPS significantly better than -$0.40, it could challenge the current cautious sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Castle Biosciences can maintain its positive earnings surprises in a competitive healthcare landscape.

Bull Confirmed If

An EPS of -$0.40 or better would confirm the bull case, suggesting strong operational performance.

Bear Confirmed If

An EPS worse than -$0.60 would confirm the bear case, indicating potential issues in the business.

Pre-Earnings Positioning

Options Market

Implied Move

±29.41%

Historical Avg

±2.5%

Pricing rich

The options market is pricing in a substantial move, suggesting that traders expect significant volatility around the earnings announcement.

Options are pricing ±29.4% while CSTL has averaged ±2.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

88.6%

Calls (300)P/C Ratio: 1.00Puts (0)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Castle Biosciences beats expectations, history suggests the stock could rise by about 1.02% on the following day, confirming positive market sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may see a muted reaction as investors await further guidance from management.

Miss

If the company misses expectations, history suggests a potential decline of around 3.10%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches or market expansions.
2Management's commentary on competitive pressures in the healthcare sector.
3Insights into customer adoption rates of their diagnostic tests.
4Any changes in operational costs or margins that could affect profitability.
5Future guidance on revenue expectations for the upcoming quarters.